Trial reportAddiction (Abingdon, England)2026
The Opioid Safety Toolkit: An interactive prescription opioid safety toolkit to increase opioid safety literacy and behaviours among people prescribed opioids for pain-a randomised controlled trial.
Trial report in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND AND
aimsPrescription opioid-related harm remains a significant public health concern. This study aimed to evaluate the efficacy of the Opioid Safety Toolkit, a co-designed, interactive online resource, in increasing naloxone uptake and healthcare provider discussions among adults prescribed opioids for pain.
designParallel-group, open-label, randomised controlled trial.
settingCommunity-based, online recruitment across Australia.
participantsAdults (n = 314) prescribed opioids for non-cancer pain.
interventionsParticipants were randomised to receive either the Opioid Safety Toolkit (intervention, n = 152), which included interactive and tailored educational content on opioid safety, or an active control website presenting evidence-based opioid safety information (n = 162). Both groups were followed for four weeks. MEASUREMENTS: The primary outcome was self-reported naloxone requests four weeks post-intervention. Other outcomes were intentions to access naloxone immediately post-intervention, and healthcare provider discussions about opioid safety at four weeks, opioid safety knowledge (immediately after the intervention and at four weeks), satisfaction with resources and naloxone possession at four weeks.
findingsParticipants in the intervention group were more likely to have requested naloxone at four weeks compared with controls [21.7% vs 9.9%, odds ratio (OR) = 2.5, 95% confidence interval (CI) = 1.3, 4.8; P = 0.005], and more likely to report intentions to access naloxone immediately post-intervention compared with controls (41.4% vs 15.4%, OR = 3.9, 95% CI = 2.3, 6.6; P < 0.001). Participants in the intervention group were not more likely to have healthcare provider discussions at four weeks compared with controls (OR = 1.1, 95% CI = 0.7, 1.8; P = 0.620). Post-intervention opioid overdose knowledge was statistically significantly higher in the intervention group compared with control group (Mean score 16.6, 95% CI = 15.5, 17.7 vs control mean score 13.3, 95% CI = 12.3, 14.3). Satisfaction with the resource was higher in the intervention group compared with control group (Mean = 20.0, 95% CI = 18.7, 21.3 vs Mean = 18.0, 95% CI = 16.7, 19.3, P = 0.035).
conclusionsWe found good evidence that, compared with a gold-standard opioid information website, the Opioid Safety Toolkit increased naloxone requests among Australian adults prescribed opioids for non-cancer pain. We also observed consistent effects across secondary outcomes, with the Toolkit increasing intentions to access naloxone, enhancing opioid overdose knowledge and yielding higher satisfaction ratings, although it did not increase healthcare provider discussions at four weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.